Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 3 - What They Never Told You

What's Going On With Hims & Hers Health Stock Today?

Hims Hers Health Inc. (NYSE:HIMS) shares are trading higher Thursday. The stock appears to be bouncing back a bit after selling off to start the week. Here’s a look at what you need to know.

Benzinga

Why Hims & Hers Stock Could Be a Multi-Bagger in the Making

Hims & Hers stock keeps giving investors more reasons to buy, and has all the right factors to turn it into a potential multi-bagger investment.

MarketBeat

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

Barchart

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

International Business Times UK

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

The Independent UK

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers Stock: Buy the Dip or Wait It Out?

Hims & Hers stock is giving up some gains after announcing the acquisition of Zava, a European digital healthcare platform.

MarketBeat

Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?

The UnitedHealth stock sell-off might have spooked investors in the medical sector, who are wondering if it will affect shares of Hims & Hers equally.

MarketBeat

Hims & Hers Stock Rises on Fundamentals and Squeeze Potential

Hims & Hers stock is now giving investors another reason to consider it a buy for the coming months, as the latest quarterly earnings show momentum.

MarketBeat

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

The Independent UK

Is Hims & Hers Stock a Buy, Sell, or Hold on Wegovy Telehealth News?

Hims & Hers stock rallies after announcing a partnership with Novo Nordisk. Analyst says there’s potential for further upside in HIMS shares.

Barchart

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating

JPMorgan's upgrade on Gilead sparks bullish sentiment for the healthcare sector—here's why stocks like Pfizer and Hims & Hers are promising opportunities.

MarketBeat

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

Barchart

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

MarketBeat

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

MarketBeat

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Fortune

Ozempic, Wegovy maker claps back at Hims & Hers Super Bowl ad: ‘Check before you inject’

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

LiveScience

Hims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugs

The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide medications aren't FDA-approved.

Fortune

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Tom’s Guide

Super Bowl commercials 2025: Post Malone Oreos, Chris Hemsworth and Chris Pratt team up, and more ads to watch right now

Plenty of brands are already sharing or teasing their Super Bowl 2025 ads. Here are all the ads we've seen during today's big game.

MarketBeat

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

208 stories

Gilead

179 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.